Last reviewed · How we verify
ARTICE
ARTICE is a small molecule that targets the underlying cause of a specific disease.
ARTICE is a small molecule that targets the underlying cause of a specific disease. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | ARTICE |
|---|---|
| Sponsor | Artcline GmbH |
| Drug class | Small molecule inhibitor |
| Target | Unknown |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
ARTICE works by inhibiting a specific enzyme, which leads to a decrease in the production of a harmful compound. This decrease in the harmful compound results in the alleviation of symptoms associated with the disease.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
- ARTICE® Real Data Collection & Observational Trial, Phase 4 Study
- Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARTICE CI brief — competitive landscape report
- ARTICE updates RSS · CI watch RSS
- Artcline GmbH portfolio CI